socalTechnews
Home
Mobile
News and Events
  • Headlines
  • Events
  • Interviews
  • Jobs
  • Directory
    		•
    Members Only
  • Networking
  • Venture Deals
  • Venture Firms
  • Companies
    • About
  • Membership
  • About
  • Contact Us
    		•
    Search News
    Wednesday, November 14, 2007

    Abraxis BioScience Spins off From APP Pharmaceuticals
    Los Angeles-based Abraxis BioScience said this morning that it has spun-off from APP Pharmaceuticals, the firm said today. The firm will focus on drug development. The firm's major product, ABRAXANE, is used for treating cancer and other illnesses. According to Abraxis, it has been capitalized with $700M in cash and it will trade on the Nasdaq Global Market as ABII.
    posted on Wednesday, November 14, 2007

    Related stories:
    > Abraxis BioScience Names CFO
    > Abraxis Bioscience Buys Manufacturing Complex From Pfizer
    > Abraxis BioScience Acquires Two Biotech Firms
    > Sequel Pharmaceuticals Spins Out, Raises $20M
    > Cadence Pharmaceuticals Scores $25M

    RSS Feed
    subscri be via emailNewsletter


    Previous news:

     Friday, September 5, 2008
    Thursday, September 4, 2008
    Wednesday, September 3, 2008
    Tuesday, September 2, 2008
    Friday, August 29, 2008